Passage Bio Net Debt/FCF

What does Passage Bio do? Passage Bio, Inc. develops genetic medicines for rare monogenic central nervous system diseases. The company focuses on six AAV-delivered therapeutics, including PBGM01 for gangliosidosis (GM1), PBFT02 for frontotemporal dementia (FTD), and PBKR03 for Krabbe disease. PBGM01 uses an AAVhu68 capsid to deliver a functional GLB1 gene encoding beta-galactosidase, PBFT02 uses AAV1 to deliver a GRN gene encoding progranulin, and PBKR03 employs AAVhu68 to deliver a GALC gene. The firm's products target specific genetic deficiencies in the central nervous system and peripheral tissues. Passage Bio's revenue model is based on developing and advancing its therapeutic pipeline. The company generates income through partnerships and potential future sales of its AAV-based therapies once approved. The primary buyers of its products are pharmaceutical companies seeking to license or co-develop these therapies. The target segments include patients with rare genetic disorders such as GM1, FTD, and Krabbe disease, who require specialized treatments due to the monogenic nature of their conditions. The firm's pipeline consists of six therapeutics, with PBGM01, PBFT02, and PBKR03 being the most advanced. These therapies are designed to address unmet medical needs in rare CNS diseases. Passage Bio's strategy involves leveraging its AAV delivery technology to create targeted treatments that can be commercialized through partnerships with larger pharmaceutical firms. Passage Bio is one of the most popular companies on Eulerpool.